News

Sense raises € 4.5 million to improve measurement of blood pressure

2012-02-13


The Danish company Sense A/S just raised € 4.5 million for their groundbreaking medical technology for blood pressure measurement. The technology works seamlessly and will remedy incorrect diagnostics of hypertension at the physicians' offices, which themselves can cause elevated readings. The total investment from venture fund SEED Capital and Vækstfonden will be used to refine the product and for commercial launch in 2013.

High blood pressure affects more than ¼ of the Western world population and it is estimated that up to 12% of all deaths can be linked to this disorder. Hypertension is therefore one of the world's largest disease areas and the most important factor in the treatment of this is an accurate diagnosis. Current diagnostic solution of choice is the measurement of blood pressure at the physicians' offices, and typically using the cuff method. However this solution has a number of challenges including discomfort with the measurement itself and nervousness during the consultation which both may contribute to erroneous measurements. In addition, the realization is that a variety of cardiovascular diseases can be diagnosed much better by measuring blood pressure over a standard 24-hour circadian rhythm, and for this the cuff method is not very suitable.

The Danish company Sense A/S develops ContiPress™, which continuously measures the patient's blood pressure 24 hours a day, down to every 10 second day and night, without the user noticing. ContiPress™ consists of an intelligent patch, which the doctor or nurse places on the patient's upper arm. From there, the unit monitors the patient's blood pressure over 24 hours and stores the data for subsequent analysis via an enclosed piece of software. The result is comprehensive data about the patient's blood pressure over 24 hours and thus an optimal basis for making the correct diagnosis.

Sense has raised € 4.5 million in an investment round with venture fund SEED Capital and Vækstfonden. It is the company third round, since it was founded in 2006 in connection with an investment from SEED Capital. Second round of investment came from SEED Capital and Vækstfonden in 2010. ContiPress™ is currently a prototype that has been clinically tested on people with very large differences in both blood pressure, BMI (body mass index) and age with promising results that verify the measurement principle. The investment round will be used to refine the device and try ContiPress™ in a more extensive clinical testing within the expected commercial launch.

Contact: 
More info: 

News archive

  • 2014-11-04

    Galecto Biotech enters agreement with Bristol-Myers Squibb

    Galecto Biotech AB today announced that the companies, together with the Galectoshareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset.

  • 2014-11-03

    SEED Capital recruits Marie-Louise Little

    “We are very happy to announce that Marie-Louse Little will join the Medtech team from November 1 2014.

  • 2014-10-16

    SEED Capital hires promising young controller

    Martin Haislund Andersen has been brought in to fill the role of controller at SEED Capital. He will be joining the administrative team on November 1.st. We are very pleased with our newest addition to SEED Capital and look forward to him joining.

  • 2014-10-14

    Leasing through GoMore is fast becoming a success

    GoMore recently launched their newest initiative in cooperation with LeasePlan. The two companies have made it possible to lease a car from LeasePlan and rent it to others through GoMore when it is not being used.

  • 2014-10-14

    Mofibo launches in Sweden and introduces new partnership

    Mofibo has experienced great success in Denmark with its service and have now expanded to the Swedish market. Mofibo has managed to get deals with 10 of the large Swedish publishers as for example Norstedts.

  • 2014-10-14

    Windar Photonics and Medichanical Engineering receives funding from The Market Development Fund

    Two of our promising portfolio companies have received funding from The Market Development Fund to create growth and new jobs. Both companies have received DKK 3M to further develop their products and get them to the market.

  • 2014-10-14

    Windar Photonics plans expansion and moves to new London office

    In September Windar Photonics moved their headquarters to London and disclosed their plan to list on the AIM stock exchange in London to fund an aggressive expansion strategy targeting Europe, China and North America.

  • 2014-10-14

    The Libratone Journey

    Libratone, the Danish wireless speaker company, was recently sold to an Asian consortium. At SEED Capital we were part of their journey from small startup to international player.

  • 2014-09-29

    Nanovi secures EUR 2.7M to market BioXmark™

    Nanovi, specialized in the development of advanced biomaterials for use in the radiotherapy of cancer, today announced it secured €2.7M to bring BioXmark™ technology to the market. BioXmark™ is a novel injectable liquid tissue marker which improves the accuracy and quality of radiation therapy.

  • 2014-09-25

    SEED Capital invests in Danish digital currency platform

    SEED Capital has invested several million DKK in the Danish bitcoin aggregator Coinify. With this investment, SEED Capital becomes the first Danish venture fund to invest in the digital currency market, a market that has been getting a lot of attention lately, especially in USA.

Social

Twitter

Recent Investments

Newsletter

Where to meet us

Press Kit

SEED Capital Ulla Brockenhuus-Schack

SEED Capital logo
Download as png (8 kb)
Download as eps (374 kb)

Ulla Brockenhuus-Schack
Download as jpg (1.1 mb)

Download our full press kit here

Contact Information
Communications Manager: Esben Søndergaard
Phone: +45 2594 0190
E-mail: ers@seedcapital.dk